Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism

Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism

Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis because it is often detected at an advanced stage, and drug resistance interferes with treatment. However, the mechanism underlying drug resistance in PDAC remains unclear. Here, we investigated metabolic changes between a par...

Full description

Bibliographic Details
Main Authors: Rina Fujiwara-Tani, Takamitsu Sasaki, Tadataka Takagi, Shiori Mori, Shingo Kishi, Yukiko Nishiguchi, Hitoshi Ohmori, Kiyomu Fujii, Hiroki Kuniyasu
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:International Journal of Molecular Sciences
Subjects:
gemcitabine
pancreatic ductal carcinoma
drug resistance
energy metabolism
ROS
Online Access:https://www.mdpi.com/1422-0067/23/14/7824

Internet

https://www.mdpi.com/1422-0067/23/14/7824

Similar Items